{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:25:14Z","timestamp":1794050714811,"version":"4.8.0"},"reference-count":100,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2023,4,28]]},"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:p>Hyperammonaemia (HA) as a consequence of numerous primary or secondary causes, gives rise to clinical manifestations due to its toxic effects on the brain. The neurological consequences broadly reflect the ammonia level, duration and age, with paediatric patients being more susceptible. Drug-induced HA may arise due to either decreased ammonia elimination or increased production. This is associated most frequently with use of valproate and presents a dilemma between ongoing therapeutic need, toxicity and the possibility of an alternative cause. As there is no specific test for drug-induced HA, prompt discussion with a metabolic physician is recommended, as the neurotoxic effects are time-dependent. Specific guidelines for managing drug-induced HA have yet to be published and hence the treatment approach outlined in this review reflects that outlined in relevant urea cycle disorder guidelines.<\/jats:p>","DOI":"10.1136\/jcp-2022-208644","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T13:53:34Z","timestamp":1683726814000},"page":"501-509","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":25,"title":["Drug-induced hyperammonaemia"],"prefix":"10.1136","volume":"76","author":[{"given":"Loai","family":"Shakerdi","sequence":"first","affiliation":[{"name":"National Centre for Inherited Metabolic Disorders, Mater Misericordiae University Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7443-689X","authenticated-orcid":false,"given":"Aidan","family":"Ryan","sequence":"additional","affiliation":[{"name":"Chemical Pathology, Cork University Hospital Biochemistry Laboratory, Cork, Ireland"},{"name":"Pathology, University College Cork College of Medicine and Health, Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"2025092610222516000_76.8.501.1","unstructured":"Network NMB . Guidelines for the investigation of hyperammonaemia. 2023. Available: https:\/\/metbio.net\/wp-content\/uploads\/MetBio-Guideline-PERE918546-10-12-2018.pdf"},{"key":"2025092610222516000_76.8.501.2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/00045632231152085","article-title":"UK national audit of the measurement of ammonia","volume":"60","author":"Aitkenhead","year":"2023","journal-title":"Ann Clin Biochem"},{"key":"2025092610222516000_76.8.501.3","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2001.111831"},{"key":"2025092610222516000_76.8.501.4","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/jimd.12292","article-title":"A retrospective study of adult patients with noncirrhotic hyperammonemia","volume":"43","author":"Stergachis","year":"2020","journal-title":"J Inherit Metab Dis"},{"key":"2025092610222516000_76.8.501.5","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.08.021102","article-title":"Global birth prevalence and mortality from inborn errors of metabolism: a systematic analysis of the evidence","volume":"8","author":"Waters","year":"2018","journal-title":"J Glob Health"},{"key":"2025092610222516000_76.8.501.6","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/jimd.12415","article-title":"Role of liver transplantation in urea cycle disorders: report from a nationwide study in Japan","volume":"44","author":"Kido","year":"2021","journal-title":"J Inherit Metab Dis"},{"key":"2025092610222516000_76.8.501.7","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12403"},{"key":"2025092610222516000_76.8.501.8","first-page":"32","article-title":"Primary hyperammonaemia: current diagnostic and therapeutic strategies","volume":"24","author":"H\u00e4berle","year":"2020","journal-title":"J Mother Child"},{"key":"2025092610222516000_76.8.501.9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1152\/physrev.1990.70.3.701","article-title":"Nitrogen metabolism and ornithine cycle function","volume":"70","author":"Meijer","year":"1990","journal-title":"Physiol Rev"},{"key":"2025092610222516000_76.8.501.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2010.02302.x"},{"key":"2025092610222516000_76.8.501.11","doi-asserted-by":"publisher","DOI":"10.1258\/acb.2011.011206"},{"key":"2025092610222516000_76.8.501.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1993.tb03253.x"},{"key":"2025092610222516000_76.8.501.13","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-012-9546-2"},{"key":"2025092610222516000_76.8.501.14","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acc.2014.09.002"},{"key":"2025092610222516000_76.8.501.15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20565"},{"key":"2025092610222516000_76.8.501.16","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1152\/physrev.1987.67.2.440","article-title":"Biochemistry and physiology of brain ammonia","volume":"67","author":"Cooper","year":"1987","journal-title":"Physiol Rev"},{"key":"2025092610222516000_76.8.501.17","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s11064-012-0955-2","article-title":"Glutamine in the pathogenesis of hepatic encephalopathy: the Trojan horse hypothesis revisited","volume":"39","author":"Rama Rao","year":"2014","journal-title":"Neurochem Res"},{"key":"2025092610222516000_76.8.501.18","doi-asserted-by":"crossref","first-page":"114343","DOI":"10.1016\/j.ab.2021.114343","article-title":"Fifteen years of urea cycle disorders brain research: looking back, looking forward","volume":"636","author":"Sen","year":"2022","journal-title":"Anal Biochem"},{"key":"2025092610222516000_76.8.501.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(71)80201-2"},{"key":"2025092610222516000_76.8.501.20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ab.2017.07.025","article-title":"Advances in methods for characterization of hepatic urea cycle enzymatic activity in HepaRG cells using UPLC-MS\/MS","volume":"535","author":"Moedas","year":"2017","journal-title":"Anal Biochem"},{"key":"2025092610222516000_76.8.501.21","article-title":"P: 65 drug-induced hyperammonaemia: data from vigibase, the WHO database","volume":"114","author":"Weiss","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"2025092610222516000_76.8.501.22","doi-asserted-by":"crossref","DOI":"10.1186\/s13613-022-01026-4","article-title":"Drug-associated hyperammonaemia: a Bayesian analysis of the who pharmacovigilance database","volume":"12","author":"Balcerac","year":"2022","journal-title":"Ann Intensive Care"},{"key":"2025092610222516000_76.8.501.23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.9740\/mhc.2021.07.243","article-title":"Hyperammonemia in patients receiving valproic acid in the hospital setting: a retrospective review","volume":"11","author":"McMorris","year":"2021","journal-title":"Ment Health Clin"},{"key":"2025092610222516000_76.8.501.24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.9740\/mhc.2018.03.073","article-title":"Valproic acid-induced hyperammonemia: incidence, clinical significance, and treatment management","volume":"8","author":"Baddour","year":"2018","journal-title":"Ment Health Clin"},{"key":"2025092610222516000_76.8.501.25","doi-asserted-by":"crossref","first-page":"107967","DOI":"10.1016\/j.yebeh.2021.107967","article-title":"Valproic acid-induced encephalopathy: a review of clinical features, risk factors, diagnosis, and treatment","volume":"120","author":"Wu","year":"2021","journal-title":"Epilepsy & Behavior"},{"key":"2025092610222516000_76.8.501.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.11.031"},{"key":"2025092610222516000_76.8.501.27","doi-asserted-by":"publisher","DOI":"10.1042\/bj3620755"},{"key":"2025092610222516000_76.8.501.28","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1982.00510210061016"},{"key":"2025092610222516000_76.8.501.29","doi-asserted-by":"crossref","first-page":"258","DOI":"10.5692\/clinicalneurol.cn-001254","article-title":"Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy","volume":"59","author":"Yamada","year":"2019","journal-title":"Rinsho Shinkeigaku"},{"key":"2025092610222516000_76.8.501.30","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.2.465"},{"key":"2025092610222516000_76.8.501.31","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(95)90295-3"},{"key":"2025092610222516000_76.8.501.32","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200104000-00013"},{"key":"2025092610222516000_76.8.501.33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ebcr.2014.09.001","article-title":"Topiramate-induced hyperammonemic encephalopathy in a patient with mental retardation: a case report and review of the literature","volume":"4","author":"Tantikittichaikul","year":"2015","journal-title":"Epilepsy Behav Case Rep"},{"key":"2025092610222516000_76.8.501.34","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(86)90429-6"},{"key":"2025092610222516000_76.8.501.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2011.05.006"},{"key":"2025092610222516000_76.8.501.36","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e3181ac3615"},{"key":"2025092610222516000_76.8.501.37","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1074"},{"key":"2025092610222516000_76.8.501.38","doi-asserted-by":"publisher","DOI":"10.1258\/000456303321016150"},{"key":"2025092610222516000_76.8.501.39","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690098"},{"key":"2025092610222516000_76.8.501.40","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejca.2020.01.019","article-title":"5-Fluorouracil-Induced hyperammonaemic encephalopathy: a French national survey","volume":"129","author":"Boil\u00e8ve","year":"2020","journal-title":"European Journal of Cancer"},{"key":"2025092610222516000_76.8.501.41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4174\/astr.2016.90.3.179","article-title":"Acute hyperammonemic encephalopathy after 5-fluorouracil based chemotherapy","volume":"90","author":"Yi","year":"2016","journal-title":"Ann Surg Treat Res"},{"key":"2025092610222516000_76.8.501.42","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1970.00480260061008"},{"key":"2025092610222516000_76.8.501.43","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006874","article-title":"Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy: a case series and review of the literature","volume":"96","author":"Mitani","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"2025092610222516000_76.8.501.44","first-page":"256","article-title":"Hyperammonemic encephalopathy associated with 5-fluorouracil in a patient with previous orthotopic liver transplantation","volume":"33","author":"Marella","year":"2020","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"2025092610222516000_76.8.501.45","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyi214"},{"key":"2025092610222516000_76.8.501.46","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-222030","article-title":"5-Fu-induced leukoencephalopathy with reversible lesion of splenium of corpus callosum in a patient with colorectal cancer","volume":"2017","author":"Acharya","year":"2017","journal-title":"BMJ Case Rep"},{"key":"2025092610222516000_76.8.501.47","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/ccr3.1422","article-title":"Hyperammonemic encephalopathy in a patient receiving fluorouracil\/oxaliplatin chemotherapy","volume":"6","author":"Ihoriya","year":"2018","journal-title":"Clin Case Rep"},{"key":"2025092610222516000_76.8.501.48","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2009.24.4.747"},{"key":"2025092610222516000_76.8.501.49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040958"},{"key":"2025092610222516000_76.8.501.50","doi-asserted-by":"publisher","DOI":"10.3747\/co.v18i1.708"},{"key":"2025092610222516000_76.8.501.51","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.suronc.2019.06.003","article-title":"Adjuvant chemotherapy in resected colon cancer: when, how and how long?","volume":"30","author":"Gelibter","year":"2019","journal-title":"Surg Oncol"},{"key":"2025092610222516000_76.8.501.52","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21228636","article-title":"Platinum-Based drugs cause mitochondrial dysfunction in cultured dorsal root ganglion neurons","volume":"21","author":"Leo","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025092610222516000_76.8.501.53","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/jns.12432","article-title":"Platinum accumulation in oxaliplatin-induced peripheral neuropathy","volume":"26","author":"Wei","year":"2021","journal-title":"J Peripher Nerv Syst"},{"key":"2025092610222516000_76.8.501.54","first-page":"335","article-title":"5-Fu-Induced hyperammonemic encephalopathy in a case of metastatic rectal adenocarcinoid successfully rechallenged with the fluoropyrimidine analog, capecitabine","volume":"31","author":"Advani","year":"2011","journal-title":"Anticancer Res"},{"key":"2025092610222516000_76.8.501.55","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1159\/000481398","article-title":"Oxaliplatin-Induced hyperammonemic encephalopathy in a patient with metastatic pancreatic cancer: a case report","volume":"10","author":"Ogata","year":"2017","journal-title":"Case Rep Oncol"},{"key":"2025092610222516000_76.8.501.56","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.184769"},{"key":"2025092610222516000_76.8.501.57","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(98)00015-8"},{"key":"2025092610222516000_76.8.501.58","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/pbc.21022","article-title":"Distinct fluctuations of ammonia levels during asparaginase therapy for childhood acute leukemia","volume":"49","author":"Steiner","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"2025092610222516000_76.8.501.59","first-page":"103","article-title":"High incidence of symptomatic hyperammonemia in children with acute lymphoblastic leukemia receiving PEGylated asparaginase","volume":"7","author":"Heitink-Poll\u00e9","year":"2013","journal-title":"JIMD Rep"},{"key":"2025092610222516000_76.8.501.60","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.2002.00993.x"},{"key":"2025092610222516000_76.8.501.61","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.56.4.481"},{"key":"2025092610222516000_76.8.501.62","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-022-02213-0","article-title":"Corticosteroid suppresses urea-cycle-related gene expressions in ornithine transcarbamylase deficiency","volume":"22","author":"Imoto","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"2025092610222516000_76.8.501.63","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(63)90554-3"},{"key":"2025092610222516000_76.8.501.64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905063401801"},{"key":"2025092610222516000_76.8.501.65","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ymgme.2022.02.001","article-title":"What are the clues for an inherited metabolic disorder in Reye syndrome? A single centre study of 58 children","volume":"135","author":"Goetz","year":"2022","journal-title":"Mol Genet Metab"},{"key":"2025092610222516000_76.8.501.66","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/jimd.12100","article-title":"Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision","volume":"42","author":"H\u00e4berle","year":"2019","journal-title":"J Inherit Metab Dis"},{"key":"2025092610222516000_76.8.501.67","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-013-9624-0"},{"key":"2025092610222516000_76.8.501.68","doi-asserted-by":"publisher","DOI":"10.1002\/humu.20813"},{"key":"2025092610222516000_76.8.501.69","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.biochi.2020.12.003","article-title":"Clinical and structural insights into potential dominant negative triggers of proximal urea cycle disorders","volume":"183","author":"Makris","year":"2021","journal-title":"Biochimie"},{"key":"2025092610222516000_76.8.501.70","first-page":"38","article-title":"Studies on the origin and significance of blood ammonia. II. The distribution of ammonia in whole blood, plasma and erythrocytes of man","volume":"39","author":"Conn","year":"1966","journal-title":"Yale J Biol Med"},{"key":"2025092610222516000_76.8.501.71","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/000456328802500603","article-title":"Reference values for analytes of 24-h urine collections known to be complete","volume":"25 (Pt 6)","author":"Bingham","year":"1988","journal-title":"Ann Clin Biochem"},{"key":"2025092610222516000_76.8.501.72","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/15563650.2017.1284333","article-title":"L-arginine in the treatment of valproate overdose-five clinical cases","volume":"55","author":"Schrettl","year":"2017","journal-title":"Clin Toxicol (Phila)"},{"key":"2025092610222516000_76.8.501.73","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1515\/cclm-2015-0591","article-title":"First data on the biological variation and quality specifications for plasma ammonia concentrations in healthy subjects","volume":"54","author":"Ucar","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"2025092610222516000_76.8.501.74","unstructured":"Management of asparaginase therapy. 2021. Available: https:\/\/www.eviq.org.au\/clinical-resources\/side-effect-and-toxicity-management\/haematological\/918-management-of-asparaginase-therapy [Accessed 9 Apr 2023]."},{"key":"2025092610222516000_76.8.501.75","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3109\/10428194.2011.596963","article-title":"Prevention and management of asparaginase\/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel","volume":"52","author":"Stock","year":"2011","journal-title":"Leukemia & Lymphoma"},{"key":"2025092610222516000_76.8.501.76","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000066","article-title":"Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy","volume":"93","author":"Tseng","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"2025092610222516000_76.8.501.77","doi-asserted-by":"crossref","first-page":"6395","DOI":"10.1007\/s00415-022-11304-7","article-title":"Risk factors and outcome of hyperammonaemia in people with epilepsy","volume":"269","author":"Vakrinou","year":"2022","journal-title":"J Neurol"},{"key":"2025092610222516000_76.8.501.78","doi-asserted-by":"crossref","DOI":"10.1007\/s11940-014-0297-2","article-title":"Management of hepatic encephalopathy","volume":"16","author":"Frontera","year":"2014","journal-title":"Curr Treat Options Neurol"},{"key":"2025092610222516000_76.8.501.79","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/jimd.12096","article-title":"Challenges in diagnosing and managing adult patients with urea cycle disorders","volume":"42","author":"Stepien","year":"2019","journal-title":"J Inherit Metab Dis"},{"key":"2025092610222516000_76.8.501.80","article-title":"Non-Absorbable disaccharides versus placebo\/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis","volume":"2016","author":"Gluud","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2025092610222516000_76.8.501.81","doi-asserted-by":"crossref","DOI":"10.3390\/nu14132755","article-title":"Recommendations for the diagnosis and therapeutic management of hyperammonaemia in paediatric and adult patients","volume":"14","author":"B\u00e9langer-Quintana","year":"2022","journal-title":"Nutrients"},{"key":"2025092610222516000_76.8.501.82","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1007\/s10545-007-0718-4","article-title":"Nutritional management of patients with urea cycle disorders","volume":"30","author":"Singh","year":"2007","journal-title":"J of Inher Metab Disea"},{"key":"2025092610222516000_76.8.501.83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2013.09.003"},{"key":"2025092610222516000_76.8.501.84","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1159\/000512100","article-title":"Extracorporeal ammonia clearance for hyperammonemia in critically ill patients: a scoping review","volume":"50","author":"Naorungroj","year":"2021","journal-title":"Blood Purif"},{"key":"2025092610222516000_76.8.501.85","doi-asserted-by":"crossref","DOI":"10.1186\/2052-0492-2-22","article-title":"Hyperammonemia due to urea cycle disorders: a potentially fatal condition in the intensive care setting","volume":"2","author":"Machado","year":"2014","journal-title":"J Intensive Care"},{"key":"2025092610222516000_76.8.501.86","doi-asserted-by":"publisher","DOI":"10.1186\/cc3742"},{"key":"2025092610222516000_76.8.501.87","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccc.2005.05.002"},{"key":"2025092610222516000_76.8.501.88","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2013.04.009"},{"key":"2025092610222516000_76.8.501.89","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.clinbiochem.2017.01.002","article-title":"Investigations of blood ammonia analysis: test matrices, storage, and stability","volume":"50","author":"Goldstein","year":"2017","journal-title":"Clin Biochem"},{"key":"2025092610222516000_76.8.501.90","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-20503-0","article-title":"Repeated measures of blood and breath ammonia in response to control, moderate and high protein dose in healthy men","volume":"8","author":"Spacek","year":"2018","journal-title":"Sci Rep"},{"key":"2025092610222516000_76.8.501.91","first-page":"133","article-title":"Observations on the effect of exercise on blood ammonia concentration in man","volume":"33","author":"Allen","year":"1960","journal-title":"Yale J Biol Med"},{"key":"2025092610222516000_76.8.501.92","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1152\/ajplegacy.1968.214.3.513","article-title":"Ammonia secretion in sweat","volume":"214","author":"Brusilow","year":"1968","journal-title":"Am J Physiol"},{"key":"2025092610222516000_76.8.501.93","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/clinchem\/22.5.663","article-title":"Technical pitfalls in measurement of venous plasma NH3 concentration","volume":"22","author":"Gerron","year":"1976","journal-title":"Clin Chem"},{"key":"2025092610222516000_76.8.501.94","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/clinchem\/31.2.332","article-title":"Effects of platelets on collection of specimens for assay of ammonia in plasma","volume":"31","author":"Cowley","year":"1985","journal-title":"Clin Chem"},{"key":"2025092610222516000_76.8.501.95","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1093\/clinchem\/36.8.1483","article-title":"Preanalytical increase of ammonia in blood specimens from healthy subjects","volume":"36","author":"da Fonseca-Wollheim","year":"1990","journal-title":"Clin Chem"},{"key":"2025092610222516000_76.8.501.96","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1177\/000456329403100507","article-title":"Use of dynamic tests of muscle function and histomorphometry of quadriceps muscle biopsies in the investigation of patients with chronic alcohol misuse and chronic fatigue syndrome","volume":"31 (Pt 5)","author":"Wassif","year":"1994","journal-title":"Ann Clin Biochem"},{"key":"2025092610222516000_76.8.501.97","doi-asserted-by":"publisher","DOI":"10.1258\/acb.2007.007088"},{"key":"2025092610222516000_76.8.501.98","doi-asserted-by":"crossref","first-page":"471","DOI":"10.5858\/arpa.2011-0445-LE","article-title":"Is the effect of hemolysis on plasma ammonia measurement overrated?","volume":"136","author":"El-Khoury","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"2025092610222516000_76.8.501.99","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2014.05.068"},{"key":"2025092610222516000_76.8.501.100","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.euroneuro.2017.03.006","article-title":"The acute effect of cannabis on plasma, liver and brain ammonia dynamics, a translational study","volume":"27","author":"Abulseoud","year":"2017","journal-title":"Eur Neuropsychopharmacol"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jcp-2022-208644","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T17:22:38Z","timestamp":1758907358000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jcp-2022-208644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":100,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,7,19]]},"published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1136\/jcp-2022-208644"],"URL":"https:\/\/doi.org\/10.1136\/jcp-2022-208644","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,10]]}}}